Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Disease course patterns in systemic lupus erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

Lupus. 2018 Dec 8:961203318817132. doi: 10.1177/0961203318817132. [Epub ahead of print]

PMID:
30526328
2.

The assessment of anxiety and depression and its associated factors in systemic lupus erythematosus.

Kwan A, Katz P, Touma Z.

Curr Rheumatol Rev. 2018 Sep 25. doi: 10.2174/1573397114666180926101513. [Epub ahead of print]

PMID:
30255761
3.

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.

van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S.

Lancet. 2018 Oct 13;392(10155):1330-1339. doi: 10.1016/S0140-6736(18)32167-6. Epub 2018 Sep 21.

PMID:
30249507
4.

Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus.

Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, Barr S, Bergeron L, Bernatsky S, Bourre-Tessier J, Clarke A, Baril-Dionne A, Dutz J, Ensworth S, Fifi-Mah A, Fortin PR, Gladman DD, Haaland D, Hanly JG, Hiraki LT, Hussein S, Legault K, Levy D, Lim L, Matsos M, McDonald EG, Medina-Rosas J, Pardo Pardi J, Peschken C, Pineau C, Pope J, Rader T, Reynolds J, Silverman E, Tselios K, Suitner M, Urowitz M, Touma Z, Vinet E, Santesso N.

J Rheumatol. 2018 Oct;45(10):1426-1439. doi: 10.3899/jrheum.171459. Epub 2018 Sep 1.

5.

Novel biological therapeutic approaches to cutaneous lupus erythematosus.

Tayer-Shifman OE, Rosen CF, Wakani L, Touma Z.

Expert Opin Biol Ther. 2018 Oct;18(10):1041-1047. doi: 10.1080/14712598.2018.1513484. Epub 2018 Sep 5.

PMID:
30118337
6.

Measuring Disease Activity and Damage with Validated Metrics: A Systematic Review on Mortality and Damage in Systemic Lupus Erythematosus.

Keeling SO, Vandermeer B, Medina J, Chatterley T, Nevskaya T, Pope J, Alaburubalnabi Z, Bissonauth A, Touma Z.

J Rheumatol. 2018 Oct;45(10):1448-1461. doi: 10.3899/jrheum.171310. Epub 2018 Aug 15.

7.

Subcutaneous belimumab in the treatment of systemic lupus erythematosus.

Elalouf O, Keeling SO, Touma Z.

Immunotherapy. 2018 Sep;10(13):1163-1173. doi: 10.2217/imt-2018-0061. Epub 2018 Aug 14.

PMID:
30105936
8.

Clinical remission and low disease activity have comparable outcomes over 10 years in systemic lupus erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

Arthritis Care Res (Hoboken). 2018 Jul 28. doi: 10.1002/acr.23720. [Epub ahead of print]

PMID:
30055090
9.

Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria.

Mosca M, Costenbader KH, Johnson SR, Lorenzoni V, Sebastiani GD, Hoyer BF, Navarra S, Bonfa E, Ramsey-Goldman R, Medina-Rosas J, Piga M, Tani C, Tedeschi SK, Dörner T, Aringer M, Touma Z.

Arthritis Rheumatol. 2019 Jan;71(1):91-98. doi: 10.1002/art.40674. Epub 2018 Nov 26.

PMID:
30035365
10.

Psoriatic Arthritis Sonographic Enthesitis Instruments: A Systematic Review of the Literature.

Elalouf O, Bakirci Ureyen S, Touma Z, Anderson M, Kaeley GS, Aydin SZ, Eder L.

J Rheumatol. 2019 Jan;46(1):43-56. doi: 10.3899/jrheum.171466. Epub 2018 Jul 15.

PMID:
30008458
11.

Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome.

Alharbi S, Ahmad Z, Bookman AA, Touma Z, Sanchez-Guerrero J, Mitsakakis N, Johnson SR.

J Rheumatol. 2018 Oct;45(10):1406-1410. doi: 10.3899/jrheum.170953. Epub 2018 Jul 15.

PMID:
30008448
12.

Monophasic Disease Course in Systemic Lupus Erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

J Rheumatol. 2018 Aug;45(8):1131-1135. doi: 10.3899/jrheum.171319. Epub 2018 Jun 1.

PMID:
29858240
13.

Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans.

Shinde R, Hezaveh K, Halaby MJ, Kloetgen A, Chakravarthy A, da Silva Medina T, Deol R, Manion KP, Baglaenko Y, Eldh M, Lamorte S, Wallace D, Chodisetti SB, Ravishankar B, Liu H, Chaudhary K, Munn DH, Tsirigos A, Madaio M, Gabrielsson S, Touma Z, Wither J, De Carvalho DD, McGaha TL.

Nat Immunol. 2018 Jun;19(6):571-582. doi: 10.1038/s41590-018-0107-1. Epub 2018 May 14.

14.

Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: Clinical/pathologic associations and etiologic mechanisms.

Wither JE, Prokopec SD, Noamani B, Chang NH, Bonilla D, Touma Z, Avila-Casado C, Reich HN, Scholey J, Fortin PR, Boutros PC, Landolt-Marticorena C.

PLoS One. 2018 May 9;13(5):e0196117. doi: 10.1371/journal.pone.0196117. eCollection 2018.

15.

A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index.

Touma Z, Gladman DD, Su J, Anderson N, Urowitz MB.

Rheumatology (Oxford). 2018 Aug 1;57(8):1370-1376. doi: 10.1093/rheumatology/key103.

PMID:
29688532
16.

Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus.

McGhie TK, Harvey P, Su J, Anderson N, Tomlinson G, Touma Z.

Clin Exp Rheumatol. 2018 Jul-Aug;36(4):545-551. Epub 2018 Apr 13.

17.

Minimal Clinically Important Difference: A Review of Outcome Measure Score Interpretation.

Engel L, Beaton DE, Touma Z.

Rheum Dis Clin North Am. 2018 May;44(2):177-188. doi: 10.1016/j.rdc.2018.01.011. Epub 2018 Feb 21. Review.

PMID:
29622290
18.

What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis.

Rayes HA, Tani C, Kwan A, Marzouk S, Colosimo K, Medina-Rosas J, Mustafa A, Su J, Lambiris P, Mosca M, Touma Z.

Semin Arthritis Rheum. 2018 Oct;48(2):240-255. doi: 10.1016/j.semarthrit.2018.02.007. Epub 2018 Feb 21.

PMID:
29571540
19.

Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments.

Touma Z, Gladman DD.

Lupus Sci Med. 2017 Dec 17;4(1):e000239. doi: 10.1136/lupus-2017-000239. eCollection 2017. Review.

20.

Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis: Results from a Single Lupus Cohort.

Fung WA, Su J, Touma Z.

Biomed Res Int. 2017;2017:5312960. doi: 10.1155/2017/5312960. Epub 2017 Aug 21.

21.

Effect of complete or partial proteinuria recovery on long-term outcomes of lupus nephritis.

Medina-Rosas J, Fung WA, Su J, Touma Z.

Semin Arthritis Rheum. 2018 Feb;47(4):557-564. doi: 10.1016/j.semarthrit.2017.07.012. Epub 2017 Aug 3.

PMID:
28888363
22.

Performance of Screening Tests for Cognitive Impairment in Systemic Lupus Erythematosus.

Nantes SG, Su J, Dhaliwal A, Colosimo K, Touma Z.

J Rheumatol. 2017 Nov;44(11):1583-1589. doi: 10.3899/jrheum.161125. Epub 2017 Sep 1.

PMID:
28864643
23.

Comparison of Spot Urine Protein to Creatinine Ratio to 24-Hour Proteinuria to Identify Important Change Over Time in Proteinuria in Lupus.

Medina-Rosas J, Su J, Cook RJ, Sabapathy A, Touma Z.

J Clin Rheumatol. 2017 Sep;23(6):301-307. doi: 10.1097/RHU.0000000000000557.

PMID:
28816766
25.

Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.

Touma Z, Sayani A, Pineau CA, Fortin I, Matsos M, Ecker GA, Chow A, Iczkovitz S.

Rheumatol Int. 2017 Jun;37(6):865-873. doi: 10.1007/s00296-017-3682-9. Epub 2017 Mar 9.

26.

Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease.

Al Rayes H, Harvey PJ, Gladman DD, Su J, Sabapathy A, Urowitz MB, Touma Z.

Arthritis Res Ther. 2017 Feb 10;19(1):31. doi: 10.1186/s13075-017-1240-1.

27.

The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort.

Yap KS, Urowitz MB, Mahood Q, Medina-Rosas J, Sabapathy A, Lawson D, Su J, Gladman DD, Touma Z.

Semin Arthritis Rheum. 2017 Jun;46(6):791-797. doi: 10.1016/j.semarthrit.2016.09.008. Epub 2016 Sep 21.

PMID:
27769590
28.

Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus.

Cramarossa G, Urowitz MB, Su J, Gladman D, Touma Z.

Lupus. 2017 Apr;26(4):365-372. doi: 10.1177/0961203316664597. Epub 2016 Aug 20.

PMID:
27522094
29.

Reply.

Polachek A, Touma Z, Anderson M, Eder L.

Arthritis Care Res (Hoboken). 2017 Mar;69(3):457. doi: 10.1002/acr.23001. No abstract available.

30.

Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.

Medina-Rosas J, Al-Rayes H, Moustafa AT, Touma Z.

Expert Opin Biol Ther. 2016 Oct;16(10):1225-38. doi: 10.1080/14712598.2016.1214263. Epub 2016 Jul 29. Review.

PMID:
27429254
31.

Systemic lupus erythematosus.

Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, Ruiz-Irastorza G, Hughes G.

Nat Rev Dis Primers. 2016 Jun 16;2:16039. doi: 10.1038/nrdp.2016.39. Review.

PMID:
27306639
32.

Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies.

Polachek A, Touma Z, Anderson M, Eder L.

Arthritis Care Res (Hoboken). 2017 Jan;69(1):67-74. doi: 10.1002/acr.22926.

33.

Clinical and Demographic Characteristics of Erosion-free and Erosion-present Status in Psoriatic Arthritis in a Cohort Study.

Touma Z, Thavaneswaran A, Chandran V, Pellett F, Cook RJ, Gladman DD.

J Rheumatol. 2016 Jun;43(6):1057-62. doi: 10.3899/jrheum.150466. Epub 2016 Apr 1.

PMID:
27036389
34.

Impact of pulmonary disease on patient-reported outcomes and patient-performed functional testing in systemic lupus erythematosus.

Fidler L, Keen KJ, Touma Z, Mittoo S.

Lupus. 2016 Aug;25(9):1004-11. doi: 10.1177/0961203316630818. Epub 2016 Feb 3.

PMID:
26846692
35.

Utility of Urinary Protein-Creatinine Ratio and Protein Content in a 24-Hour Urine Collection in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.

Medina-Rosas J, Yap KS, Anderson M, Su J, Touma Z.

Arthritis Care Res (Hoboken). 2016 Sep;68(9):1310-9. doi: 10.1002/acr.22828. Epub 2016 Jul 29. Review.

36.

Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus.

Medina-Rosas J, Gladman DD, Su J, Sabapathy A, Urowitz MB, Touma Z.

Arthritis Res Ther. 2015 Oct 24;17:296. doi: 10.1186/s13075-015-0808-x.

37.

SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement.

Touma Z, Gladman DD, Su J, Ibañez D, Urowitz MB.

J Rheumatol. 2015 Aug;42(8):1401-5. doi: 10.3899/jrheum.141088. Epub 2015 Jun 15.

PMID:
26077403
38.

DEVELOPING AN IPAD® APPLICATION FOR DATA COLLECTION IN A RHEUMATOLOGY RESEARCH CLINIC.

Kaka H, Ayearst R, Tran M, Touma Z, Bagovich M, Vinik O, Somaily M, Haddad A, Gladman DD, Chandran V.

Int J Technol Assess Health Care. 2015 Jan;31(1-2):99-102. doi: 10.1017/S0266462315000069. Epub 2015 May 20.

PMID:
25991410
39.

Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus.

Al Rayes H, Touma Z.

Drug Des Devel Ther. 2014 Nov 17;8:2303-10. doi: 10.2147/DDDT.S49778. eCollection 2014. Review.

40.

Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment.

Touma Z, Urowitz MB, Ibañez D, Gladman DD.

J Rheumatol. 2014 Apr;41(4):688-97. doi: 10.3899/jrheum.130005. Epub 2014 Jan 15.

PMID:
24429170
41.

The assessment of disease activity in rheumatic diseases.

Arayssi T, Touma Z, Nikpour M, Ghandour L.

Int J Rheumatol. 2013;2013:275691. doi: 10.1155/2013/275691. Epub 2013 Nov 7. No abstract available.

42.

Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus.

Dua AB, Touma Z, Toloza S, Jolly M.

Curr Rheumatol Rep. 2013 Dec;15(12):380. doi: 10.1007/s11926-013-0380-9. Review.

PMID:
24178589
43.

Development, sensibility, and reliability of the Toronto Axial Spondyloarthritis Questionnaire in inflammatory bowel disease.

Alnaqbi KA, Touma Z, Passalent L, Johnson SR, Tomlinson GA, Carty A, Inman RD.

J Rheumatol. 2013 Oct;40(10):1726-35. doi: 10.3899/jrheum.130048. Epub 2013 Sep 1.

PMID:
23996291
44.

GRAPPA Trainees Symposium 2012: a report from the GRAPPA 2012 annual meeting.

Garg N, Touma Z, Ritchlin CT.

J Rheumatol. 2013 Aug;40(8):1413-8. doi: 10.3899/jrheum.130452.

PMID:
23908535
45.

Systemic lupus erythematosus disease activity index 2000 responder index-50 website.

Touma Z, Urowitz MB, Gladman DD.

J Rheumatol. 2013 May;40(5):733. doi: 10.3899/jrheum.130030. No abstract available.

PMID:
23637378
46.

Vaccination and auto-immune rheumatic diseases: lessons learnt from the 2009 H1N1 influenza virus vaccination campaign.

Touma Z, Gladman DD, Urowitz MB.

Curr Opin Rheumatol. 2013 Mar;25(2):164-70. doi: 10.1097/BOR.0b013e32835d2b7b. Review.

PMID:
23370371
47.

Systemic lupus erythematosus: an update on current pharmacotherapy and future directions.

Touma Z, Urowitz MB, Gladman DD.

Expert Opin Biol Ther. 2013 May;13(5):723-37. doi: 10.1517/14712598.2013.764411. Epub 2013 Jan 23. Review.

PMID:
23339281
48.

Skin nontuberculous mycobacterial infection in systemic lupus erythematosus: an unusual skin infection mimicking lupus vasculitis.

Touma Z, Haddad A, Gladman DD, Uleryk EM, Urowitz MB.

Semin Arthritis Rheum. 2013 Apr;42(5):498-506. doi: 10.1016/j.semarthrit.2012.08.002. Epub 2013 Jan 16. Review.

PMID:
23332736
49.

Development and assessment of users' satisfaction with the systemic lupus erythematosus disease activity index 2000 responder index-50 website.

Touma Z, Gladman DD, MacKinnon A, Carette S, Abu-Shakra M, Askanase A, Nived O, Hanly JG, Landolt-Marticorena C, Tam LS, Toloza S, Nikpour M, Riddell C, Steiman A, Eder L, Haddad A, Barber C, Urowitz MB.

J Rheumatol. 2013 Jan;40(1):34-9. doi: 10.3899/jrheum.120754. Epub 2012 Nov 1.

PMID:
23118108
50.

SLEDAI-2K Responder Index 50 captures 50% improvement in disease activity over 10 years.

Touma Z, Gladman DD, Ibañez D, Urowitz MB.

Lupus. 2012 Oct;21(12):1305-11. Epub 2012 Jul 16.

PMID:
22800940

Supplemental Content

Support Center